Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 456

1.

Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.

Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ.

Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17356-61. doi: 10.1073/pnas.0809154105. Epub 2008 Oct 31.

2.

Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo.

Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC.

Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):1850-5. doi: 10.1073/pnas.1011379108. Epub 2011 Jan 13.

3.

Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy.

Kolishetti N, Dhar S, Valencia PM, Lin LQ, Karnik R, Lippard SJ, Langer R, Farokhzad OC.

Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):17939-44. doi: 10.1073/pnas.1011368107. Epub 2010 Oct 4.

4.

Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.

Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R.

Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6315-20. Epub 2006 Apr 10.

5.

Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery.

Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX, Levy-Nissenbaum E, Radovic-Moreno AF, Langer R, Farokhzad OC.

Biomaterials. 2007 Feb;28(5):869-76. Epub 2006 Oct 20.

6.

Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.

Wu X, Ding B, Gao J, Wang H, Fan W, Wang X, Zhang W, Wang X, Ye L, Zhang M, Ding X, Liu J, Zhu Q, Gao S.

Int J Nanomedicine. 2011;6:1747-56. doi: 10.2147/IJN.S23747. Epub 2011 Aug 19.

7.

α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug.

Graf N, Bielenberg DR, Kolishetti N, Muus C, Banyard J, Farokhzad OC, Lippard SJ.

ACS Nano. 2012 May 22;6(5):4530-9. doi: 10.1021/nn301148e. Epub 2012 May 14.

8.

Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers.

Gu F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, Langer R, Farokhzad OC.

Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2586-91. doi: 10.1073/pnas.0711714105. Epub 2008 Feb 13.

9.

Polymeric nanoparticles for drug delivery.

Chan JM, Valencia PM, Zhang L, Langer R, Farokhzad OC.

Methods Mol Biol. 2010;624:163-75. doi: 10.1007/978-1-60761-609-2_11.

PMID:
20217595
10.

Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device.

Dhar S, Liu Z, Thomale J, Dai H, Lippard SJ.

J Am Chem Soc. 2008 Aug 27;130(34):11467-76. doi: 10.1021/ja803036e. Epub 2008 Jul 29.

11.

Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.

Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R.

Cancer Res. 2004 Nov 1;64(21):7668-72.

12.

Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells.

Li L, Xiang D, Shigdar S, Yang W, Li Q, Lin J, Liu K, Duan W.

Int J Nanomedicine. 2014 Feb 21;9:1083-96. doi: 10.2147/IJN.S59779. eCollection 2014.

13.

Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells.

Gryparis EC, Hatziapostolou M, Papadimitriou E, Avgoustakis K.

Eur J Pharm Biopharm. 2007 Aug;67(1):1-8. Epub 2007 Jan 12.

PMID:
17303395
14.

Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery.

Gu F, Langer R, Farokhzad OC.

Methods Mol Biol. 2009;544:589-98. doi: 10.1007/978-1-59745-483-4_37.

15.

Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex.

Kim E, Jung Y, Choi H, Yang J, Suh JS, Huh YM, Kim K, Haam S.

Biomaterials. 2010 Jun;31(16):4592-9. doi: 10.1016/j.biomaterials.2010.02.030. Epub 2010 Mar 4.

PMID:
20206379
16.
17.

Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA).

Chandran SS, Banerjee SR, Mease RC, Pomper MG, Denmeade SR.

Cancer Biol Ther. 2008 Jun;7(6):974-82. Epub 2008 Mar 26.

18.

Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics.

Marrache S, Dhar S.

Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16288-93. doi: 10.1073/pnas.1210096109. Epub 2012 Sep 18.

19.

Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads.

Dhar S, Daniel WL, Giljohann DA, Mirkin CA, Lippard SJ.

J Am Chem Soc. 2009 Oct 21;131(41):14652-3. doi: 10.1021/ja9071282. Erratum in: J Am Chem Soc. 2010 Dec 8;132(48):17335. J Am Chem Soc. 2010 Mar 3;132(8):2845.

20.

Targeted delivery of Epirubicin to cancer cells by PEGylated A10 aptamer.

Taghdisi SM, Danesh NM, Sarreshtehdar Emrani A, Tabrizian K, Zandkarimi M, Ramezani M, Abnous K.

J Drug Target. 2013 Sep;21(8):739-44. doi: 10.3109/1061186X.2013.812095. Epub 2013 Jul 1.

PMID:
23815443
Items per page

Supplemental Content

Write to the Help Desk